The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What planet is management living on.......
AstraZeneca is saying your product is not good enough, so we'll give it a try
$150k is like 10p for AstraZeneca
what an insult!!!!!!!
It's stupidly cheap at these prices and cashed up to Q2 2025 to boot. Imagine the mega deals that will land between now and then!
Carrot you lost all credibility when you slipped up and gave the game away by 'inadvertently' posting on this BB that you were a day trader dumping stock...then when you got caught out and couldn't remove the post....tried back peddling to cover your tracks that your not a LTH as claimed but a day trader 'ramping' the stock hence all the day in day out copy and paste drivel which you don't actually understand or even care!...and you have the nerve calling others liars .. hilarious!
AZ if happy with the technology of AGL will just buy them out, AZ spending a few hundred million is like me and you spending 10p
GLA
A third of the year almost gone and no signs of that additional £6m revenues needed to avert an imminent cash placement doesn't bode well imho!
3.57% up now.
You better trade it out fast EC!..😉
Wow that much lol!
Up 1.79%.
£150k really, was that really worth an RNS?..
So Newland where is the £6m of additional revenues needed to avoid a cash placement as we head into H2 this year?
@luqs
“I don't know people come on these boards to spread total lies”
“Target price increased shows significance of the deal”
Can you please direct me to the increased target price?
I don't know people come on these boards to spread total lies
All very promising for the medium - long term.
But there’s a short term funding requirement and even that’s based on a forecast trebling of revenues - from unspecified sources.
This remains a massive high risk high reward stock imo.
I would expect to see at least another couple of lab contract announcements before mid year.
As far as the lab services business goes it is becoming clear that there are 2 pipelines.
Pipeline 1 : Pharma engages Angle to develop an assay (£150-£250K) -> pharma uses assay in P1/P2 trial (£0.5-£1m)->pharma uses assay in P3 trial (£2-£3m)->pharma uses assay in companion diagnostic (£multi million per annum)
Pipeline 2 : Same as above but skips the assay development step i.e. the pharma uses an assay already developed by Angle.
What matters now is the number of contracts at the start of this pipeline as this will give good visibility into likely future revenue as each project moves through the stages of the pipeline. In the forthcoming results the number for last year are largely irrelevant - what really matters is the insight provided into the growth of the above pipelines and outlook statement. I would hope that by now Angle are able to establish a more accurate view of how many of their 'prospects' will turn into customers.
ANGLE plc
LON: AGL
OverviewFinancialsCompare
13.87 GBX −1.63 (10.54%)today
25 Apr, 16:30 BST • Disclaimer
POP..POP..POP!
No I mean Bye Bye..
Bantham.
EC - i have a bad feeling about this…..
============================
The idea is you buy LOW and then sell HIGH.
It seems to me the sp is low now...............
LOL!
EC - i have a bad feeling about this…..
Bantham.
Very negative you are.
Just bought 10k @ 14.295p.
We know they are having business dealings with both Astrazenica and Eisai Inc.
And they talk to Illumina and Thermo Fisher regularly.
More contracts to come............. it's obvious!
The Force is not so strong with Newland anymore.
IMHO this contract was much more significant than Eisai ( even if for a paltry £150k ).
But the spike was unexciting and the fall back rapid.
Credibility and belief have been lost.
Not a pretty outlook.
Ceo is on Bloomberg
No need to sell very cheap will double ....great time to top up